Results 61 to 70 of about 1,224,792 (212)

Treatment approaches in posthypoxic myoclonus: A narrative review with expert opinion

Epilepsia, Volume 67, Issue 3, Page 1049-1065, March 2026.
Abstract Acute posthypoxic myoclonus (PHM) is a neurological complication that typically emerges within 12–48 h following cardiac arrest, often in comatose patients. It can present as generalized, multifocal, or focal myoclonus and has traditionally been associated with poor prognosis.
Marina Romozzi, Federico Tosto, David García‐Azorín, Luigi Francesco Iannone, Catello Vollono, Paolo Calabresi, Juan Luis Alcala‐Zermeno, Michael R. Sperling   +7 more
wiley   +1 more source

Clinical and polysomnographic course of childhood narcolepsy with cataplexy. [PDF]

, 2013
Our aim was to investigate the natural evolution of cataplexy and polysomnographic features in untreated children with narcolepsy with cataplexy. To this end, clinical, polysomnographic, and cataplexy-video assessments were performed at diagnosis (mean ...
American Academy of Sleep Medicine, Aran, Aran, Broughton, Cacciari, Christian Franceschini, Cvetkovic-Lopes, Dale, Dauvilliers, Dauvilliers, Elena Finotti, Emmanuel Mignot, Fabio Pizza, Faraco, Francesca Ingravallo, Giuseppe Plazzi, Guilleminault, Hallmayer, Han, Hanna Peltola, Hor, Kailash P. Bhatia, Kawashima, Kornum, Kornum, Kotagal, Lecendreux, Ling Lin, Lino Nobili, Luca, Ludvikova, Mark J. Edwards, Markku Partinen, Mascaro, Mignot, Mignot, Murali, Ohayon, Oliviero Bruni, Overeem, Partinen, Plazzi, Poli, Poli, Ponz, Rubboli, Schreyer, Schwartz, Serra, Stefano Vandi, Sundvik, Tafti, Vendrame, Vetrugno, Vignatelli, von Herrath, Wingerchuk, Yamuy, Yves Dauvilliers   +58 more
core   +2 more sources

Emergency department presentations, hospitalisations and police seizure data related to gamma‐hydroxybutyrate (GHB) in New South Wales, Australia, from 2015 to 2024

Addiction, Volume 121, Issue 2, Page 305-315, February 2026.
Abstract Background and aims Gamma‐hydroxybutyrate (GHB) is an endogenous neurochemical and illicit synthetic drug. Its precursors, gamma‐butyrolactone (GBL) and 1,4‐butanediol (1,4‐BD), are often used as substitutes. We aimed to describe GHB‐related harms in New South Wales (NSW), Australia.
Krista J. Siefried, Janette L. Smith, Christine A. Harvey, Anthony Nedanoski, Jared A. Brown, Una Cullinan, Nadine Ezard, Thanjira Jiranantakan, Darren M. Roberts, Jonathan Brett   +9 more
wiley   +1 more source

Increasing Evidence for the Use of Sodium Oxybate in Multi-Drug-Resistant Lance–Adams Syndrome

Tremor and Other Hyperkinetic Movements, 2019
Background: Treatment of posthypoxic myoclonus (PHM) can be a challenge in patients not responsive to first-line medications. PMH is a rare condition that has a dramatic impact on patients’ quality of life. Refractory cases are not uncommon. Case report:
Giulietta M. Riboldi, Steven J. Frucht
doaj   +1 more source

The use of medications approved for alcohol use disorders in Italy

Frontiers in Public Health, 2023
BackgroundItaly has the highest per capita alcohol consumption among European countries. Several pharmacological treatments for alcohol use disorders (AUDs) are currently available in Italy, but no consumption data are available.
Filomena Fortinguerra, Andrea Pierantozzi, Francesco Trotta   +2 more
doaj   +1 more source

Effectiveness and optimization of low-sodium oxybate in participants with narcolepsy switching from a high-sodium oxybate: data from the Substitution of Equal Grams of Uninterrupted Xyrem to Xywav study. [PDF]

J Clin Sleep Med
Low-sodium oxybate (LXB; calcium, magnesium, potassium, and sodium oxybates; Xywav) contains the same active moiety as high-sodium oxybates (SXBs; SXB [Xyrem] and fixed-dose SXB [Lumryz]), with 92% less sodium, and is approved in the United States for ...
Macfadden W, Leary EB, Fuller DS, Kirby MT, Roy A.   +4 more
europepmc   +2 more sources

Expanding the Genetic and Phenotypic Spectrum of DYT‐VPS16: The Importance of Splice‐Site Variants

Movement Disorders, Volume 41, Issue 1, Page 84-94, January 2026.
Abstract Background DYT‐VPS16, an early‐onset isolated dystonia caused by variants in the VPS16 gene, has been reported in fewer than 70 patients. Methods We explored the clinical and genotypic spectrum of DYT‐VPS16 by investigating early‐onset dystonia patients with VPS16 variants discovered in our large Biodatabank and through gene‐matching ...
Ana Westenberger, Edgard Verdura, Mandy Radefeldt, Leslie E. Sanderson, Kornelia Tripolszki, Anna Marcé‐Grau, Ana Cazurro‐Gutiérrez, Anita Nikoncuk, Rebecca Herzog, Ruslan Al‐Ali, Mariana Ferreira, Ligia S. Almeida, Tainá Regina Damaceno Silveira, Suliman Khan, Raphael Doyle Maia, Péter Klivényi, András Salamon, Volkan Baltaci, Asli Subasioglu, Jeanette Prada‐Arismendy, Goran Čuturilo, Sebastian Loens, Vera Tadic, Isabelle Maystadt, Deniz Karadurmus, Barbara Leube, Jonathan De Winter, Alice Monticelli, Liesbeth De Waele, Jonathan Baets, Mateja Vinkšel, Aleš Maver, Lorena Tschopp, Gabriela Ziegler, Ana Sanguinetti, Katja Lohmann, Tahsin Stefan Barakat, Peter Bauer, Belén Perez‐Dueñas, Aida M. Bertoli‐Avella   +39 more
wiley   +1 more source

Sodium Oxybate: A Cause of Extreme Involuntary Weight Loss in a Young Lady

Case Reports in Medicine, 2019
We present a case of a young lady with extreme involuntary weight loss and alarming constitutional symptoms found ultimately to be all due to a single medication’s side effects.
Michael G. Noujaim, Ahmad Mourad, Jeffrey D. Clough   +2 more
doaj   +1 more source

Interaction between γ-Hydroxybutyric Acid and Ethanol: A Review from Toxicokinetic and Toxicodynamic Perspectives

Metabolites, 2023
Gamma-hydroxybutyric acid (GHB) is a potent, short-acting central nervous system depressant as well as an inhibitory neurotransmitter or neuromodulator derived from gamma-aminobutyric acid (GABA), a major inhibitory neurotransmitter.
Suryun Jung, Mingyu Kim, Suji Kim, Sooyeun Lee   +3 more
doaj   +1 more source

Narcolepsy: Pathophysiology, Diagnosis, Management, and Future Directions, a Narrative Review

Brain and Behavior, Volume 15, Issue 12, December 2025.
This visual summary outlines the pathophysiology of narcolepsy, driven by hypocretin loss, and details its clinical diagnosis, current management strategies, and the shift toward future disease‐modifying therapies like orexin agonists and immunomodulation.
Natasha Elaine Hastings, Khalil El Abdi, Fazeela Bibi, Bilal Aslam, Milka Rosario Nuñez, Muhammad Tahla Rehman Sherani, Sujeet Shadmani, Umama Alam, Vohra Maham Hassan, Hoor‐e‐Ainaa, Hania Imran, James Hanna, Said Hamid Sadat   +12 more
wiley   +1 more source